Although chimeric antigen receptor T cells (CAR-T) therapy specifically targeting B cell antigens such as CD19 and CD22 benefited (for some cases) of refractory or relapsed B-ALL (R/R B-ALL), exhaustion and relapse of CAR-T after CAR-T therapy had limited its long-term efficiency [4]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.